CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Seraph 100 Filterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02914132
NCT02914132N/ACompleted
CompareCT.gov

Safety and Performance Evaluation of the Seraph® 100 Microbind® Affinity Blood Filter for Reducing Bacteremia in Patients on Hemodialysis

ExThera Medical Corporation·interventional·Posted Sep 26, 2016·Updated Aug 12, 2019

In Brief

A clinical study evaluating Seraph 100 Filter for Bacteremia and Bacterial Infection. Completed, enrolled 15 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine whether the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is safe in the treatment of dialysis patients with bacteremia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacteremia, Bacterial Infection
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 26, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJun 7, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.8 years ago

Interventions

Seraph 100 Filterdevice

Treatment of renal replacement therapy patients with bacteremia.